What question did this study set out to answer?

To review the evidence, guideline recommendations, and clinical utility of prothrombin complex concentrates for managing bleeding complications associated with direct oral anticoagulants.

December 1, 2018International Journal of Emergency MedicineOpen Access

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review

View Full Paper

Ask AI

Bookmark

Why the study?

Treatment options for managing direct oral anticoagulant-associated bleeding are limited, and evidence regarding prothrombin complex concentrates as a potential therapeutic option is increasing.

Does prothrombin complex concentrate improve haemostasis and reverse coagulopathy in patients with DOAC-associated bleeding?

Key Points

To review the evidence, guideline recommendations, and clinical utility of prothrombin complex concentrates for managing bleeding complications associated with direct oral anticoagulants.
Synthesized findings from preclinical models, healthy volunteer studies, and clinical observational investigations evaluating direct oral anticoagulant reversal.
Reviewed contemporary clinical practice guidelines and emerging evidence regarding specific Factor Xa inhibitor reversal agents.
Evidence from preclinical models, healthy volunteers, and observational studies supports prothrombin complex concentrates as an effective intervention for direct oral anticoagulant-induced coagulopathy.
Multiple clinical practice guidelines specifically recommend prothrombin complex concentrates to manage direct oral anticoagulant-associated bleeding.
Optimal restoration of haemostasis in direct oral anticoagulant-associated coagulopathy increasingly relies on a multimodal clinical approach as targeted reversal agents continue to develop.

Structured PICO

Does prothrombin complex concentrate improve haemostasis and reverse coagulopathy in patients with DOAC-associated bleeding?

Population

Patients presenting with DOAC-associated bleeding, as well as healthy volunteers and preclinical models receiving DOACs (dabigatran, rivaroxaban, apixaban, edoxaban).

Intervention

Prothrombin complex concentrates (PCCs), including 3-factor (3F-PCC), 4-factor (4F-PCC), and activated PCCs (aPCC).

Comparator

Placebo, saline control, or conservative management (varies across reviewed studies).

Outcome

Reversal of DOAC-induced coagulopathy as measured by laboratory parameters (PT, ETP, TGA) and clinical bleeding outcomes (haemostasis, bleeding duration/volume).

PCCs represent a potential therapeutic option for restoring haemostasis in patients with DOAC-associated bleeding, supported by emerging observational data and clinical practice guidelines.

Limitations

Many studies supporting PCC have used preclinical models and healthy volunteers rather than bleeding patients.

Implication

Observational data support PCC for DOAC bleeding; leaves open need for RCTs to guide practice.

Abstract

BACKGROUND: Bleeding complications are a risk associated with all anticoagulants. Currently, the treatment options for the management of direct oral anticoagulant (DOAC)-associated bleeding are limited. Prothrombin complex concentrates (PCCs) have been proposed as a potential therapeutic option, and evidence regarding their use is increasing. REVIEW: Many studies supporting PCC have used preclinical models and healthy volunteers; however, more recently, observational studies have further improved insight into current DOAC reversal strategies. Multiple clinical practice guidelines now specifically suggest use of PCCs for this indication. Specific reversal agents for Factor Xa inhibitors may become available in the near future, but data on their efficacy are still emerging. CONCLUSIONS: Ultimately, a multimodal approach may be the optimal strategy to restore haemostasis in patients presenting with DOAC-associated coagulopathy.

Discussion

No takes yet. Share an insight, caveat, or question.

Figures from the paper

Published by International Journal of Emergency Medicine · CC BY

Cite This Study

Hoffman et al. (2018) studied this question.

synapsesocial.com/papers/6a70ac7be71d69abee08c690 https://doi.org/10.1186/s12245-018-0215-6

View Full Paper

Ask AI

Bookmark

Implication

Observational data support PCC for DOAC bleeding; leaves open need for RCTs to guide practice.

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Figures from the paper

Cite This Study

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Figures from the paper

Cite This Study

Keep reading

Keep reading